Why PhaseBio's stock price more than doubled today
March 18, 2019 at 09:30 AM EDT
The Malvern biopharmaceutical company reported positive results for an early-stage study of its experimental reversal agent for a blood thinning medicine.
Breaking News Bar
Business News and Information
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
| ||||||
bottom clear
